WO2023111811 - TREATMENT OF ALLERGIC REACTIONS USING ANTI-IGE ANTIBODIES
National phase entry:
Publication Number
WO/2023/111811
Publication Date
22.06.2023
International Application No.
PCT/IB2022/062066
International Filing Date
12.12.2022
Title **
[English]
TREATMENT OF ALLERGIC REACTIONS USING ANTI-IGE ANTIBODIES
[French]
TRAITEMENT DE RÉACTIONS ALLERGIQUES À L'AIDE D'ANTICORPS ANTI-IGE
Applicants **
NOVARTIS AG
Inventors
BOTTOLI, Ivan
CABANSKI, Maciej
EGGER, Anna
GAUTIER, Aurelie
KAWAKAMI, Fernando Takeshi
Priority Data
63/289,373
14.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2202 | |
| EPO | Filing, Examination, Granting | 8795 | |
| Japan | Filing, Examination, Granting | 2154 | |
| South Korea | Filing, Examination, Granting | 2066 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
19,957
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to methods for modifying the course of a disease or disorder involving IgE, in particular an IgE mediated allergic reactions to one or more allergens, in subjects having such disease or condition.[French]
La présente invention concerne des procédés pour modifier l'évolution d'une maladie ou d'un trouble impliquant l'IgE, en particulier une réaction allergique médiée par l'IgE à un ou plusieurs allergènes, chez des sujets présentant une telle maladie ou un tel état.